US FDA Approves First Treatment for Rare Genetic Disorder Prader-Willi Syndrome
(Reuters) -The U.S. Food and Drug Administration on Wednesday approved Soleno Therapeutics' drug to treat a rare genetic ...
Zacks.com on MSN3d
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug
Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating ...
BioSpace3d
Soleno Wins First FDA Approval for Hyperphagia in Prader-Willi Syndrome
Vykat XR is specifically indicated to address hyperphagia, or the abnormally strong sensation of hunger, which often leads to ...
AOL4d
US FDA approves first treatment for rare genetic disorder Prader-Willi syndrome
The syndrome's symptoms appear immediately, with infants born with low muscle tone ... Anthony Holland, president of the International Prader-Willi Syndrome Organisation said the IPWSO will ...
Nasdaq3d
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug
extended-release tablets for treating hyperphagia in adults and children aged four years and older with Prader-Willi syndrome (PWS). The company expects to launch the drug in the United States in ...
Hosted on MSN19d
Prader-Willi Syndrome Symptoms and Treatment
Although rare, Prader-Willi syndrome is the most common genetic cause of obesity. At first, an infant with Prader-Willi syndrome will have trouble growing and gaining weight (failure to thrive).